Brief: Inhibikase Therapeutics files for mixed shelf of up to $300 mln
20/06/2025 22:14
June 20 (Reuters) - Inhibikase Therapeutics Inc IKT.O: INHIBIKASE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING INHIBIKASE THERAPEUTICS : SALES AGREEMENT PROSPECTUS COVERING OFFERING OF UP TO $200 MILLION COMMON STOCK THAT MAY BE ISSUED FROM TIME TO TIME Source text: [ID:n0001193125-25-143738] Further company coverage: IKT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share